Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug

Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure

Fineline Cube Jan 16, 2024

Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase...

Company Drug

CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine

Fineline Cube Jan 16, 2024

CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...

Company Deals

Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline

Fineline Cube Jan 16, 2024

Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...

Company Deals

Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success

Fineline Cube Jan 16, 2024

Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...

Company Drug

RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer

Fineline Cube Jan 16, 2024

China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...

Company Drug

CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors

Fineline Cube Jan 16, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...

Company Deals

BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs

Fineline Cube Jan 15, 2024

Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...

Company Deals

NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference

Fineline Cube Jan 15, 2024

At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a...

Company Deals

Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis

Fineline Cube Jan 15, 2024

Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...

Company Drug

MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment

Fineline Cube Jan 15, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...

Company Deals

Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator

Fineline Cube Jan 15, 2024

Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic...

Policy / Regulatory

China’s NHSA Unveils Measures to Secure Volume-Based Procurement Supply

Fineline Cube Jan 15, 2024

The National Healthcare Security Administration (NHSA) has issued a notification outlining key measures to ensure...

Company Drug

BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan

Fineline Cube Jan 15, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...

Company Deals

Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion

Fineline Cube Jan 15, 2024

EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of...

Company Deals

Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer

Fineline Cube Jan 15, 2024

Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...

Company Drug

CARsgen Therapeutics Gets NMPA Approval for CAR-T Therapy CT011 in Hepatocellular Carcinoma

Fineline Cube Jan 15, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from...

Company Drug

Simcere Pharmaceutical Group Gets NMPA Green Light for USP1 Inhibitor SIM0501

Fineline Cube Jan 15, 2024

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

Ant Insurance Reports 23% Surge in Health Insurance Payouts, Processing 4.69 Million Claims in 2023

Fineline Cube Jan 12, 2024

Ant Insurance, a platform integrated within Alibaba’s Alipay app, reported a 23% year-on-year increase in...

Company Deals

Myrobalan Therapeutics Secures $24 Million in Series A Funding with Strong Chinese Investor Support

Fineline Cube Jan 12, 2024

Myrobalan Therapeutics, a Massachusetts-based biotech firm, has successfully completed a $24 million Series A funding...

Company Drug

Huadong Medicine’s Relmapirazin Approval Filing Accepted by NMPA for GFR Measurement

Fineline Cube Jan 12, 2024

Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that its market approval...

Posts pagination

1 … 361 362 363 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.